Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patients

Weight-Loss Drug Zepbound Resolves Sleep Apnea in Up to 52% of Patients, Lilly Says

Eli Lilly has announced that its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients during two late-stage trials. The company, based in the U.S., is in a race with Danish rival Novo Nordisk to get their obesity drugs approved to treat other ailments as well. Notably, Novo's Wegovy was approved as a treatment for heart disease in March, and Lilly's own heart-disease trial for Zepbound is expected to conclude this year.